Researchers from Pritzker Molecular Engineering, under the guidance of Prof. Jeffrey Hubbell, demonstrated that their compound can eliminate the autoimmune response linked to multiple sclerosis. Researchers at the University of Chicago's Pritzker School of Molecular Engineering (PME) have developed

Seems that trials are already happening. As a person living with UC, this could be a game changer.

    • ColdCreasent@lemmy.caEnglish
      34·
      1 year ago

      TLDR would be that any autoimmune disease could see this helping. It “removes/erases” the white blood cells memory of the bodily molecule that we don’t want destroyed from their list of things to destroy.

        • ColdCreasent@lemmy.caEnglish
          3·
          1 year ago

          With my beginner understanding of the immune response, they could if this is successful. Since allergies are the immune response to an external stimuli instead of an internal stimuli like an autoimmune disorder.

      • Weslee@lemmy.worldEnglish
        1·
        1 year ago

        Thank you! That sounds like amazing progress, between this and CRISPR’s progress with cancer, the future looks good for anyone suffering from these

  • SilenceInTheVoid@lemmy.worldEnglish
    4·
    1 year ago

    If this works out it would be a game changer, though most likely also priced as such especially if it is a one hit solution for diseases such as MS as there is a lot of money being made out of the current medication, hopefully it doesn’t get buried.

    • SatanicNotMessianic@lemmy.mlEnglish
      4·
      1 year ago

      It’s be a bit premature to do that, if you’re interested as a patient or layperson. It will also be all over the news in five years or so if it works and they bring it to market.

      However, it looks like you could make an alert for the company name (Anokion SA) if you’re interested.

      Those trials are conducted by the pharmaceutical company Anokion SA, which helped fund the new work and which Hubbell cofounded and is a consultant, board member, and equity holder

  • Jo@mastodon.social
    21·
    1 year ago

    @baruchin The technology seems relatively simple and low-risk: tag a molecule with a specific sugar… I wonder if this is something biohackers can manage to do before clinical trials and Big Pharma approval. If so, sign me up! #biohacking

    • deafboy@lemmy.worldEnglish
      31·
      1 year ago

      Not tonight, Pinky…

      phase I safety trials have already been carried out in people with celiac disease, an autoimmune disease that is associated with eating wheat, barley, and rye, and phase I safety trials are underway in multiple sclerosis.

      I know, I know. Safety studies do not judge the effectiveness, but at least they’ve actually moved on from mice to humans this time.